Advertisement
Canada markets open in 8 hours 56 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • Bitcoin CAD

    87,852.45
    +119.79 (+0.14%)
     

  • CMC Crypto 200

    1,386.50
    +3.93 (+0.28%)
     

  • GOLD FUTURES

    2,347.30
    +4.80 (+0.20%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,767.75
    +200.25 (+1.14%)
     

  • VOLATILITY

    15.37
    -15.97 (-50.96%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,955.91
    +327.43 (+0.87%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Today’s Research Reports on Stocks to Watch: OPKO Health and Exact Sciences

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / November 13, 2018 / OPKO Health was seeing big gains in Monday’s session on a stellarthird quarter report. Shares of Exact Sciences Corp. were plummeting despite any remarkable news to explain the 8.54% drop at the close.

RDI Initiates Coverage on:

OPKO Health, Inc.
https://rdinvesting.com/news/?ticker=OPK

Exact Sciences Corporation
https://rdinvesting.com/news/?ticker=EXAS

OPKO Health, Inc. shares were up 20.55% on Monday on about 8.4 million shares traded. The healthcare company saw its shares explode after reporting third quarter financial results that topped analysts' expectations this past Friday. For the quarter OPKO reported a net loss of $22.7 million, or 5 cents a share. This was a lot better than the 8 cents a share loss that analysts were expecting andwas also better than the 6 cent loss the company reported in theyear ago quarter. Revenue for the quarter was $249.8 million. It was in September that the SEC alleged fraud by both the company and its Chairman & CEO Phil Frost. Litigation had been filed against Frost, Opko Health Inc., and multiple other related entities and individuals. The SEC complaint read, "In every scheme, Honig, and some combination of Stetson, Brauser, O'Rourke,Groussmanand Frost, either explicitly or tacitly agreed to buy, hold or sell their shares in coordination with one another, knowing that a pump and dump was in the offing that would allow them all to profit handsomely."

ADVERTISEMENT

Access RDI’s OPKO Health, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OPK

Exact Sciences Corporation shares were down 8.54% at the close on Monday with nearly 2.7 million shares traded. There was no relevant news from the company yesterday to explain the loss. The molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer will be presenting at the Jefferies 2018 London Healthcare Conference on Thursday, Nov. 15 at 2:40 p.m. GMT, 9:40 a.m. EST as well as the Evercore ISI HealthconX in Boston on Tuesday, Nov. 27 at 12:30 p.m. EST. It was in October that the company reportedthird quarter earnings with CEO Kevin T. Conroy stating, "During the third quarter, Exact Sciences made significant progress on our 3 annual priorities, and in the fight against colon cancer. Highlights for the quarter include 63% revenue growth, accelerating physician demand, 75% gross margin, and efficient capital deployment. Most importantly, we screened an additional 241,000 people with Cologuard. Based on these strong results, we're raising our revenue guidance for the year." The Company raised its full-year outlook to $435 million to $440 million of revenue fromprior range of $420 million to $430 million. This assumes 910,000 completed Cologuard tests.

Access RDI’s Exact Sciences Corporation Research Report at:
https://rdinvesting.com/news/?ticker=EXAS

Our Actionable Research on OPKO Health, Inc. (NASDAQ: OPK) and Exact Sciences Corporation (NASDAQ: EXAS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com